Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Mikiya ISHIHARA

Mie University Hospital

Japan

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Immunology

70%

Cell Biology

30%

T Cell Biology

50%

Immunotherapy

40%

Immunomodulation

30%

Cancer Therapy

30%

Stem Cell Transplantation

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence

Year:

2023

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Year:

2023

A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

Year:

2023

Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Year:

2023

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

Year:

2022

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

Year:

2022

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition (Breast Cancer, (2020), 27, 3, (322-331), 10.1007/s12282-020-01085-0)

Year:

2021

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

Year:

2020

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

Year:

2020

A case of extragonadal germ cell tumor treated by induction therapy with a reduced bep regimen

Year:

2020

CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression

Year:

2020

Collaborators4

Yoshihiro Miyahara

Professor

Mie university

JAPAN

Minoru Miyashita

Tohoku University

JAPAN

Hiroshi Shiku

-

JAPAN

Yoshihiro Nishida

Nagoya University Hospital

JAPAN

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI